title: Alpha-1-noradrenergic inhibition of growth hormone secretion is mediated through the paraventricular hypothalamic nucleus in male rats.
abstract: In the present work we investigated a possible role of an alpha 1-noradrenergic (NA) pathway involving the hypothalamic paraventricular nucleus (PVN) in the central regulation of growth hormone (GH) release. A week after bilateral electrolytic lesions of the PVN, pulsatile GH-secretory patterns were monitored in unanesthetized, freely moving control or lesioned male rats. While the pulsatility of GH secretion was maintained, the amplitude of the pulses and the area under the curve during an 8-hour sampling period were twice as high in PVN-lesioned than in control rats. Trough levels of GH were similar in the two groups. Inactivation of PVN alpha 1-receptors by local infusion of an alpha 1-NA antagonist, prazosin (50 ng/rat), also induced an increase in GH release. In control animals, intravenous injection of the alpha 1-NA agonist methoxamine (0.02 mg/100 g body weight) elicited a decrease in GH release but was ineffective when administered to PVN-lesioned rats. These data show that alpha 1-NA receptors, mediating GH inhibition, are located in the PVN. In light of the analogous effects observed herein on PVN-lesioned animals and, previously, after locus coeruleus (LC) lesions it is suggested that GH inhibition by the LC is relayed by the PVN via a local alpha 1-receptor population.
authors.affiliation: Unité de Recherches de Dynamique des Systèmes Neuroendocriniens, INSERM U159, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Mounier
authors.forename: M T
authors.initials: MT
authors.lastname: Bluet-Pajot
authors.forename: D
authors.initials: D
authors.lastname: Durand
authors.forename: C
authors.initials: C
authors.lastname: Kordon
authors.forename: J
authors.initials: J
authors.lastname: Epelbaum
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D013006:Growth Hormone / Q000009:adverse effects* / Q000378:metabolism; D008297:Male; D008729:Methoxamine / Q000494:pharmacology; D009638:Norepinephrine / Q000502:physiology*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D012016:Reference Values
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D011942:Receptors, Adrenergic, alpha; D013006:Growth Hormone; D008729:Methoxamine; D009638:Norepinephrine; D011224:Prazosin